Agent | Odronextamab | Mosunetuzumab | Epcoritamab | Glofitamab |
---|---|---|---|---|
Targets | CD20, CD3 | CD20, CD3 | CD20, CD3 | CD20, CD3 |
IG | Human IgG4 | Human IgG1 | Human IgG1 | Human IgG |
Administration | i.v | s.c | i.v | i.v |
Patients (n) | 35 | 22 | 18 | 28 |
Median prior therapy | 3 (1–11) | 4 (1–8) | NA | 3 (1–12) |
Prior CAR T | 69% | 22% | NA | NA |
ORR | 44% | 60% | 67% | 50% |
CR | 38% | 20% | 33% | 29% |
PFS | NR | NR | NR | NR |
OS | NR | NR | NR | NR |
CRS, any grade | 63% | 21% | 58% | 57.9% |
≥ 3 | 5% | 0 | 0 | 3.8% |
NT, any grade | 0 | 22% | 9% | 0 |
≥ 3 | 0 | 0 | 3% | 0 |
Reference | [24] | [25] | [26] | [27] |
ASH,2020, #400 | ASH,2020, #401 | ASH,2020, #403 | ASH,2020, #404 |